Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
ConditionEnd Stage Chronic Renal Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age13+
SponsorOman Ministry of Health
About this trial
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis.
Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation.
The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.
Eligibility criteria
Qualifiers
o age equal to or more than13 years.
All genders.
All patients undergoing chronic Peritoneal Dialysis.
Urine output equal or more than 150 ml/24 hours.
Disqualifiers
o Age less than 13 years
Patients with type I diabetes mellitus.
Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D).
Patients with urine output less than 150 ml/24hours.
Trial design
Treatments tested in this trial
- Dapagliflozin
Treatment groups
38 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov